Dartmouth + Innovation + Cancer

Many discoveries now revolutionizing the prevention and treatment of cancer can be traced back to Dartmouth—including immunotherapies for solid tumors, the integration of palliative care with cancer care, and the identification of cancer risks from environmental toxins and behaviors.
Source: News at Dartmouth Medical School - Category: Hospital Management Authors: Tags: Donor Impact Insider News Research campaign cancer Home-feature Interaction Norris Cotton Cancer Center Source Type: news

Related Links:

ConclusionsThe emergence of new drugs for mCRPC has improved treatment options dramatically. Currently, systemic treatment options for mCRPC include hormonal therapy, chemotherapy, immunotherapy, and radionuclide therapy as well as bone-modifying agents and palliative or supportive measures. Further, new genetically targeted agents (PARP inhibitors and PD-1 inhibitors) are on the horizon for certain subsets of biomarker-selected patients. The best strategies for patient selection and optimal sequential use to achieve the longest cumulative survival improvement and to prevent early resistance remain unclear.Patient summaryT...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C Abstract The management of Non-Small Cell Lung Cancer (NSCLC) has changed dramatically in the last 10 years with an increase in the understanding of the biology and with the development of new and multiple treatments. Chemotherapy being the first systemic treatment used in the setting of advanced disease, proving benefit for patients over palliative care. With the identification of oncogenic drivers, innovative targeted therapies were developed and tested, leading to important changes in the management of certain patients and giving to some of...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Lung large-cell neuroendocrine carcinoma (L-LCNEC) accounts for 2 –3 % of all lung cancers. It is a high-grade neuroendocrine carcinoma with some cytological features of non-small-cell lung cancer (NSCLC), but it also has biological, clinical, and prognostic characteristics of small-cell lung cancer (SCLC). Diagnosis is based on histological features consistent with NSCLC and identification, by immunohistochemistry (IHC), of at least one neuroendocrine marker. The prognosis is poor, with 5-year overall survival rates of 13–57% for all, 27–62% for early, and
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Clear cell carcinoma is the most common form of renal cell carcinoma (RCC). Metastatic RCC is poorly responsive to treatment and has a bleak prognosis. Newer systemic agents have improved outcomes. Furthermore, their interaction with radiation treatment (RT) may provide further therapeutic options. RCC is considered to be radioresistant, however we report the case of a patient with progression on targeted therapy and immunotherapy who achieved a substantial and sustained local, and possibly abscopal, response to low dose palliative radiation therapy.Case Rep Oncol 2018;11:756 –762
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
This article highlights the evidence-based data to support systemic treatment options for patients with head and neck squamous cell carcinoma (HNSCC). The discovery of the human papillomavirus epidemic in HNSCC and its favorable prognosis has led to a major focus of research. Patients are stratified into clinical or pathologic risk categories and enrolled in trials comparing standard treatment paradigms with deintensification, in low-risk disease, or to intensification, in intermediate-risk or high-risk disease. Immunotherapy has proven beneficial in second-line palliative therapy and is under investigation in first-line p...
Source: The Surgical Clinics of North America - Category: Surgery Authors: Tags: Oral Maxillofac Surg Clin North Am Source Type: research
This article highlights the evidence-based data to support systemic treatment options for patients with head and neck squamous cell carcinoma (HNSCC). The discovery of the human papillomavirus epidemic in HNSCC and its favorable prognosis has led to a major focus of research. Patients are stratified into clinical or pathologic risk categories and enrolled in trials comparing standard treatment paradigms with deintensification, in low-risk disease, or to intensification, in intermediate-risk or high-risk disease. Immunotherapy has proven beneficial in second-line palliative therapy and is under investigation in first-line p...
Source: Oral and Maxillofacial Surgery Clinics - Category: ENT & OMF Authors: Source Type: research
Authors: Möckelmann N, Münscher A Abstract Whereas surgical treatment of thyroid carcinoma plays an important role especially in the early stages, a multimodal approach is pursued in the palliative setting, which, in addition to classical chemotherapy primarily involves treatment with tyrosine kinase inhibitors. An analysis of clinical trials and studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 is presented. In particular, studies on the treatment of radioiodine-refractory differentiated thyroid cancer, anaplastic thyroid cancer and immunotherapy were selected...
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
ConclusionOur patient population had good short ‐term survival outcomes despite most receiving palliative treatment. Cancer patients can achieve positive outcomes after ICU admission and appropriate selection of patients is crucial.This article is protected by copyright. All rights reserved.
Source: Internal Medicine Journal - Category: Internal Medicine Authors: Tags: Original Article Source Type: research
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma. They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto. “There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Lung Cancer, Nonsmall Cell;   Lung Cancer Intervention:   Radiation: Radiation combined with immunotherapy Sponsor:   University Health Network, Toronto Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Environmental Health | Hospital Management | Immunotherapy | Palliative | Palliative Care